Immunization

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Retrieved on: 
Thursday, October 26, 2023
Urinary tract infection, FDA, NYSE, Food, BioNTech, Vaccine, SARS-CoV-2, FAAM, GMT, MD, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Influenza, Senior, Pfizer, Vaccination, Clinical trial, COVID-19, Risk, Viral, Head, BNTX, Safety, PFE, Immunization, Patient

In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Key Points: 
  • In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
  • The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
  • “We are encouraged by these early results in our Phase 1/2 study of our combination vaccine candidates against influenza and COVID-19.
  • Pfizer and BioNTech previously announced that their mRNA-based combination vaccine candidate for influenza and COVID-19 received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

Retrieved on: 
Thursday, October 26, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Mouse, Infection, RNA, Antigen, CD4, CMC, Vaccine, CD8, VBI, Disease, Messenger, Autoimmune disease, MLE, Human body, Allergy, Cancer, Chemistry, Immunization

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA).

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company’s current proprietary eVLP technology by coding the particles in messenger RNA (mRNA).
  • In preclinical studies, VBI’s new mRNA-launched eVLP (MLE) technology has demonstrated an ability to generate stronger B- and T-cell signals than those seen with other mRNA vaccines tested.
  • The MLE technology also has the added benefit of streamlined and accelerated chemistry, manufacturing, and control (CMC) processes and manufacturing timelines, similar to other known mRNA vaccine production platforms.
  • “Our MLE technology uses the human body as a bioreactor to produce complex proteins that mimic the natural viral targets, stimulating a strong functional immune response.

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Retrieved on: 
Thursday, October 26, 2023
COVID-19, Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Urinary tract infection, FDA, NYSE, Food, BioNTech, Vaccine, SARS-CoV-2, FAAM, GMT, MD, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Influenza, Senior, Pfizer, Vaccination, Inc., Clinical trial, Risk, Viral, Head, BNTX, Safety, PFE, Immunization, Patient

In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Key Points: 
  • In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
  • The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
  • “We are encouraged by these early results in our Phase 1/2 study of our combination vaccine candidates against influenza and COVID-19.
  • Pfizer and BioNTech previously announced that their mRNA-based combination vaccine candidate for influenza and COVID-19 received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

PharmaJet, Nigeria’s National Primary Health Care Development Agency, and Health-focused Consortium Begin Implementation of Study Using Tropis® ID for Routine Immunization

Retrieved on: 
Tuesday, October 24, 2023
General Health, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Vaccine hesitancy, Government, Policy, Peritonitis, International development, Vaccine, Polio, Global Polio Eradication Initiative, Use, Injection, Multimedia, Criticism of the United States government, USAID, IPV, Syringe, Jhpiego, Immunization, United, PATH

Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.

Key Points: 
  • Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.
  • View the full release here: https://www.businesswire.com/news/home/20231024060890/en/
    Nigerian baby receiving polio vaccine with the PharmaJet Tropis® Precision Needle-free System.
  • Evidence from the study is intended to inform policy regarding intradermal delivery of polio vaccine in routine immunization settings.
  • Study preparation included the development of standard operating procedures to ensure congruence with the country’s existing medical guidelines.

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Retrieved on: 
Wednesday, October 18, 2023
Hepatocyte, The Mark of Gideon, Hepatitis B virus, The Journal of Infectious Diseases, Immunization, Antigen, Liver, Arenavirus, Journal, Gilead Sciences, Vaccination, Disease, Hepatitis, Safety, Infection, HBV, Vaccine, Pharmaceutical industry

The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.

Key Points: 
  • The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.
    HB-400 is an alternating, 2-vector non-replicating arenaviral therapeutic vaccine for the treatment of chronic hepatitis B.
  • It uses the Lymphocytic Choriomeningitis Virus and Pichinde Virus as arenaviral backbones, with each expressing three highly conserved hepatitis B virus antigens.
  • HB-400 is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences, Inc.
  • “The lack of curative therapies for chronic hepatitis B infection is a significant barrier to addressing the global burden of disease,” said Joern Aldag, Chief Executive Officer at HOOKIPA.

Radisys Applauds Engage Digital Platform Winners in TADHack Global 2023

Retrieved on: 
Monday, October 23, 2023
Apps, Applications, Mobile, Wireless, Technology, Telecommunications, Software, Networks, Internet, Hardware, IOT (Internet of Things), Artificial Intelligence, Digital, G-network, Human, Internet access, STT, Hacks, Device, API, Auditory processing disorder, Visage SDK, Particulates, EDP, AI, Immunization, Digital platform, Communication, Parent, Video game, Radisys

Radisys® Corporation , a global leader of open telecom solutions, is pleased to congratulate the winners of TADHack Global 2023 , the world’s premier global hackathon focusing on programmable communication solutions.

Key Points: 
  • Radisys® Corporation , a global leader of open telecom solutions, is pleased to congratulate the winners of TADHack Global 2023 , the world’s premier global hackathon focusing on programmable communication solutions.
  • The TADHack Global event, sponsored by Radisys, was held October 21-22, 2023, ahead of Network X, an industry-leading broadband network event for enterprises and telcos.
  • “I am pleased to extend my congratulations to all participants and winners of TADHack Global 2023," said Al Balasco, Head of Devices and Digital Engagement Platforms Business, Radisys.
  • “Radisys' Engage Digital Platform provides developers with the unique capabilities and necessary tools to create integrated AI and communication solutions that solve particular business problems and address common community challenges.”

Onymos Partners with the University of Cincinnati to Develop Innovative Document Conversion and Data Validation Tool

Retrieved on: 
Thursday, October 19, 2023
Internet of things, Digital, OCR, Smartphone, Health, Assistant, Physician, Organization, University, Student, Partnership, Space Applications Services, Immunization, Nursing, SAN, Integrated Data Store, Logic, Management, Salesforce

SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, today announced its newest customer, the University of Cincinnati. The goal of this partnership was to enable the University of Cincinnati to create an innovative new tool that will enable the rapid, accurate, and secure conversion, validation, and entry of healthcare data from thousands of students. This will ultimately provide the university's healthcare staff with even more time to focus on student health and wellness rather than paperwork.

Key Points: 
  • The goal of this partnership was to enable the University of Cincinnati to create an innovative new tool that will enable the rapid, accurate, and secure conversion, validation, and entry of healthcare data from thousands of students.
  • Additionally, manual data entry is known to generate errors that can go unnoticed in healthcare data and record systems.
  • "We are honored to have the opportunity to work with the University of Cincinnati to develop their application through our Features-as-a-Service platform."
  • For more information on Onymos, its Features-as-a-Service platform, DocKnow, or how it can help your education institution, visit Onymos.com .

DHSS launches interactive statewide flu dashboard

Retrieved on: 
Friday, October 13, 2023
Missouri Department of Health and Senior Services, Health, COVID-19, Antibody, Advisory Committee on Immunization Practices, Food, Death, Vaccine, Cough, Influenza-like illness, Food and Drug Administration, Hospital, Advisory Committee, Immunization, CDC, Safety, Season, Missouri Department of Social Services, Education, Vaccination, DHSS, Virus, Data, Fever, Infection, Influenza, RSV, Patient, Management, The Missourians

It is available as an interactive online dashboard , launched today.

Key Points: 
  • It is available as an interactive online dashboard , launched today.
  • The first week of this official flu season, Oct. 1-7, showed low flu activity with 125 laboratory-confirmed cases of influenza A and B reported statewide.
  • The dashboard streamlines the previous weekly flu reports , which DHSS has produced for many years during each official flu season (October through mid-May).
  • “This dashboard is another example of our continued commitment to modernizing the data we collect, analyze and share with Missourians,” said DHSS Director Paula F. Nickelson.

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Retrieved on: 
Monday, October 9, 2023
Patent, Infection, Matrix (biology), Cancer, COVID-19, GeoVax, Death, Vaccine, Weight loss, Intellectual property, Survival, Biotechnology, MVA, FDA, Vaccination, Immunization, Virus-like particle, VP40, Viremia

ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.

Key Points: 
  • ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.
  • A recent presentation of data from nonhuman primate studies demonstrated that immunization with GeoVax’s vaccine candidate, GEO-MM01, conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus.
  • GeoVax is currently evaluating study designs to assess the potential for administering different dose levels of the vaccine and different routes of vaccine delivery to optimize utility and efficacy.
  • This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.”

Pro football players team up for 'Punts for Purpose' on behalf of Compassion International

Retrieved on: 
Friday, October 13, 2023
Commander, Malnutrition, Mercedes-Benz Stadium, Infant, Tress Way, Compassion, Pinion, Way, Compassion International, Punt, Atlanta Falcons, Mortality, Prenatal care, 2016 Atlanta Falcons season, Hunger, Education, Poverty, Washington Commanders, Immunization, Mother, Corey Bojorquez, Bradley Pinion, Child, Athlete, Cleveland Browns, Falcon, Holiday, Surveying, Birth control

COLORADO SPRINGS, Colo., Oct. 13, 2023 /PRNewswire/ -- This Sunday, the Washington Commanders face the Atlanta Falcons at Mercedes-Benz Stadium. However, as opposing punters Bradley Pinion, Falcons, and Tress Way, Commanders, approach game day, they'll be punting for a bigger purpose. For each punt that lands inside the 20-yard line, both Pinion and Way have committed to donate $1,000 to child development organization Compassion International to fight poverty in an initiative called "Punts for Purpose."

Key Points: 
  • However, as opposing punters Bradley Pinion, Falcons, and Tress Way, Commanders, approach game day, they'll be punting for a bigger purpose.
  • And approximately 99 percent of maternal and 90 percent of neonatal mortalities occur in the developing world.
  • Ashleigh Alcorn, manager of pro athlete partnerships at Compassion, expressed, "Compassion loves partnering with pro athletes to bring attention to children living in abject poverty.
  • We're also all on Team God – the only team that truly matters."